{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T14:16:08Z","timestamp":1779372968237,"version":"3.53.1"},"reference-count":21,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCEH","J Clin Exp Hematopathol"],"published-print":{"date-parts":[[2021]]},"DOI":"10.3960\/jslrt.20047","type":"journal-article","created":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T22:19:11Z","timestamp":1610057951000},"page":"53-57","source":"Crossref","is-referenced-by-count":20,"title":["Acquired amegakaryocytic thrombocytopenia after durvalumab administration"],"prefix":"10.3960","volume":"61","author":[{"given":"Takahiro","family":"Suyama","sequence":"first","affiliation":[{"name":"Departments of Internal Medicine,Nippon Koukan Hospital, Kawasaki, Kanagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masao","family":"Hagihara","sequence":"additional","affiliation":[{"name":"Department of Hematology, Eiju General Hospital, Taito, Tokyo, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto","family":"Kubota","sequence":"additional","affiliation":[{"name":"Pathology, Nippon Koukan Hospital, Kawasaki, Kanagawa, Japan,"},{"name":"Department of Pathology, Keio University School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Osamura","sequence":"additional","affiliation":[{"name":"Pathology, Nippon Koukan Hospital, Kawasaki, Kanagawa, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Shinka","sequence":"additional","affiliation":[{"name":"Departments of Internal Medicine,Nippon Koukan Hospital, Kawasaki, Kanagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Miyao","sequence":"additional","affiliation":[{"name":"Departments of Internal Medicine,Nippon Koukan Hospital, Kawasaki, Kanagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2349","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Calvo R. Hematological side effects of immune checkpoint inhibitors: the example of immune-related thrombocytopenia. Front Pharmacol. 2019; 10: 454.","DOI":"10.3389\/fphar.2019.00454"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Delanoy N, Michot JM, Comont T et al.<\/i> Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study. Lancet Haematol. 2019; 6: e48-e57.","DOI":"10.1016\/S2352-3026(18)30175-3"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Young A, Quandt Z, Bluestone JA. The balancing act between cancer immunity and autoimmunity in response to immunotherapy. Cancer Immunol Res. 2018; 6: 1445-1452.","DOI":"10.1158\/2326-6066.CIR-18-0487"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Ahmad S, Lewis M, Corrie P, Iddawela M. Ipilimumab-induced thrombocytopenia in a patient with metastatic melanoma. J Oncol Pharm Pract. 2012; 18: 287-292.","DOI":"10.1177\/1078155211411001"},{"key":"5","doi-asserted-by":"crossref","unstructured":"6 Bagley SJ, Kosteva JA, Evans TL, Langer CJ. Immune thrombocytopenia exacerbated by nivolumab in a patient with non-small-cell lung cancer. Cancer Treat Commun. 2016; 6: 20-23.","DOI":"10.1016\/j.ctrc.2016.02.009"},{"key":"6","doi-asserted-by":"crossref","unstructured":"7 Kanameishi S, Otsuka A, Nonomura Y et al.<\/i> Idiopathic thrombocytopenic purpura induced by nivolumab in a metastatic melanoma patient with elevated PD-1 expression on B cells. Ann Oncol. 2016; 27: 546-547.","DOI":"10.1093\/annonc\/mdv580"},{"key":"7","doi-asserted-by":"crossref","unstructured":"8 Le Roy A, Kempf E, Ackermann F et al.<\/i> Two cases of immune thrombocytopenia associated with pembrolizumab. Eur J Cancer. 2016; 54: 172-174.","DOI":"10.1016\/j.ejca.2015.10.073"},{"key":"8","doi-asserted-by":"crossref","unstructured":"9 Le Burel S, Champiat S, Mateus C et al.<\/i> Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1\/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis. Eur J Cancer. 2017; 82: 34-44.","DOI":"10.1016\/j.ejca.2017.05.032"},{"key":"9","doi-asserted-by":"crossref","unstructured":"11 Pf\u00f6hler C, Eichler H, Burgard B et al.<\/i> A case of immune thrombocytopenia as a rare side effect of an immunotherapy with PD1-blocking agents for metastatic melanoma. Transfus Med Hemother. 2017; 44: 426-428.","DOI":"10.1159\/000479237"},{"key":"10","doi-asserted-by":"crossref","unstructured":"12 Shiuan E, Beckermann KE, Ozgun A et al.<\/i> Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy. J Immunother Cancer. 2017; 5: 8.","DOI":"10.1186\/s40425-017-0210-0"},{"key":"11","doi-asserted-by":"crossref","unstructured":"13 Jotatsu T, Oda K, Yamaguchi Y et al.<\/i> Immune-mediated thrombocytopenia and hypothyroidism in a lung cancer patient treated with nivolumab. Immunotherapy. 2018; 10: 85-91.","DOI":"10.2217\/imt-2017-0100"},{"key":"12","doi-asserted-by":"crossref","unstructured":"14 Hasegawa T, Ozaki Y, Inoue T et al.<\/i> Nivolumab-related severe thrombocytopenia in a patient with relapsed lung adenocarcinoma: a case report and review of the literature. J Med Case Reports. 2019; 13: 316.","DOI":"10.1186\/s13256-019-2245-y"},{"key":"13","unstructured":"15 Mori H, Sakai C, Iwai M et al.<\/i> Immune thrombocytopenia induced by nivolumab in a patient with non-small cell lung cancer. Respir Med Case Rep. 2019; 28: 100871."},{"key":"14","doi-asserted-by":"crossref","unstructured":"16 Mouri A, Kaira K, Shiono A, Miura Y, Kagamu H. Severe thrombocytopenia associated with pembrolizumab in a patients with non-small cell lung cancer (NSCLC): A case report and literature review. In Vivo. 2020; 34: 877-880.","DOI":"10.21873\/invivo.11852"},{"key":"15","doi-asserted-by":"crossref","unstructured":"17 Kuwana M, Okazaki Y, Kajihara M et al.<\/i> Autoantibody to c-Mpl (thrombopoietin receptor) in systemic lupus erythematosus: relationship to thrombocytopenia with megakaryocytic hypoplasia. Arthritis Rheum. 2002; 46: 2148-2159.","DOI":"10.1002\/art.10420"},{"key":"16","doi-asserted-by":"crossref","unstructured":"18 Kuwana M, Kaburaki J, Okazaki Y, Miyazaki H, Ikeda Y. Two types of autoantibody-mediated thrombocytopenia in patients with systemic lupus erythematosus. Rheumatology. 2006; 45: 851-854.","DOI":"10.1093\/rheumatology\/kel010"},{"key":"17","doi-asserted-by":"crossref","unstructured":"19 Gewirtz AM, Sacchetti MK, Bien R, Barry WE. Cell-mediated suppression of megakaryocytopoiesis in acquired amegakaryocytic thrombocytopenic purpura. Blood. 1986; 68: 619-626.","DOI":"10.1182\/blood.V68.3.619.619"},{"key":"18","doi-asserted-by":"crossref","unstructured":"20 Benedetti F, de Sabata D, Perona G. T suppressor activated lymphocytes (CD8 + \/DR +) inhibit megakaryocyte progenitor cell differentiation in a case of acquired amegakaryocytic thrombocytopenic purpura. Stem Cells. 1994; 12: 205-213.","DOI":"10.1002\/stem.5530120209"},{"key":"19","doi-asserted-by":"crossref","unstructured":"21 Agarwal N, Spahr JE, Werner TL, Newton DL, Rodgers GM. Acquired amegakaryocytic thrombocytopenic purpura. Am J Hematol. 2006; 81: 132-135.","DOI":"10.1002\/ajh.20510"},{"key":"20","doi-asserted-by":"crossref","unstructured":"22 Nishino S, Kodaka T, Sawada Y et al.<\/i> Marked rebound thrombocytosis in response to glucocorticoids in a patient with acquired amegakaryocytic thrombocytopenia. J Clin Exp Hematop. 2018; 58: 166-170.","DOI":"10.3960\/jslrt.18016"},{"key":"21","doi-asserted-by":"crossref","unstructured":"23 Mukai HY, Kojima H, Todokoro K et al.<\/i> Serum thrombopoietin (TPO) levels in patients with amegakaryocytic thrombocytopenia are much higher than those with immune thrombocytopenic purpura. Thromb Haemost. 1996; 76: 675-678.","DOI":"10.1055\/s-0038-1650641"}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/61\/1\/61_20047\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,20]],"date-time":"2021-03-20T04:34:33Z","timestamp":1616214873000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/61\/1\/61_20047\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.20047","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"value":"1346-4280","type":"print"},{"value":"1880-9952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021]]}}}